1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Lentivirus Manufacturing for Advanced Therapies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Lentivirus Manufacturing for Advanced Therapies Market, by Application
8.1.1 Gene Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Vaccines/Vaccinology
8.1.2.1. Market Revenue and Forecast
8.1.3. Cancer Immunotherapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. Lentivirus Manufacturing for Advanced Therapies Market, by End-User
9.1.1. Pharmaceutical & Biotechnology Companies
9.1.1.1. Market Revenue and Forecast
9.1.2. Research Institutes & Academic Institutions
9.1.2.1. Market Revenue and Forecast
9.1.3. CROs/CDMOs
9.1.3.1. Market Revenue and Forecast
9.1.4. Others (hospitals, clinical-trial sponsors)
9.1.4.1. Market Revenue and Forecast
10.1. Lentivirus Manufacturing for Advanced Therapies Market, by Scale of Operation
10.1.1. Clinical/Pilot-scale Production
10.1.1.1. Market Revenue and Forecast
10.1.2. Commercial/Large-scale Production
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application
11.1.2. Market Revenue and Forecast, by End-User
11.1.3. Market Revenue and Forecast, by Scale of Operation
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application
11.1.4.2. Market Revenue and Forecast, by End-User
11.1.4.3. Market Revenue and Forecast, by Scale of Operation
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application
11.1.5.2. Market Revenue and Forecast, by End-User
11.1.5.3. Market Revenue and Forecast, by Scale of Operation
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application
11.2.2. Market Revenue and Forecast, by End-User
11.2.3. Market Revenue and Forecast, by Scale of Operation
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application
11.2.4.2. Market Revenue and Forecast, by End-User
11.2.4.3. Market Revenue and Forecast, by Scale of Operation
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application
11.2.5.2. Market Revenue and Forecast, by End-User
11.2.5.3. Market Revenue and Forecast, by Scale of Operation
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application
11.2.6.2. Market Revenue and Forecast, by End-User
11.2.6.3. Market Revenue and Forecast, by Scale of Operation
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application
11.2.7.2. Market Revenue and Forecast, by End-User
11.2.7.3. Market Revenue and Forecast, by Scale of Operation
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application
11.3.2. Market Revenue and Forecast, by End-User
11.3.3. Market Revenue and Forecast, by Scale of Operation
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application
11.3.4.2. Market Revenue and Forecast, by End-User
11.3.4.3. Market Revenue and Forecast, by Scale of Operation
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application
11.3.5.2. Market Revenue and Forecast, by End-User
11.3.5.3. Market Revenue and Forecast, by Scale of Operation
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application
11.3.6.2. Market Revenue and Forecast, by End-User
11.3.6.3. Market Revenue and Forecast, by Scale of Operation
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application
11.3.7.2. Market Revenue and Forecast, by End-User
11.3.7.3. Market Revenue and Forecast, by Scale of Operation
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application
11.4.2. Market Revenue and Forecast, by End-User
11.4.3. Market Revenue and Forecast, by Scale of Operation
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application
11.4.4.2. Market Revenue and Forecast, by End-User
11.4.4.3. Market Revenue and Forecast, by Scale of Operation
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application
11.4.5.2. Market Revenue and Forecast, by End-User
11.4.5.3. Market Revenue and Forecast, by Scale of Operation
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application
11.4.6.2. Market Revenue and Forecast, by End-User
11.4.6.3. Market Revenue and Forecast, by Scale of Operation
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application
11.4.7.2. Market Revenue and Forecast, by End-User
11.4.7.3. Market Revenue and Forecast, by Scale of Operation
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application
11.5.2. Market Revenue and Forecast, by End-User
11.5.3. Market Revenue and Forecast, by Scale of Operation
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application
11.5.4.2. Market Revenue and Forecast, by End-User
11.5.4.3. Market Revenue and Forecast, by Scale of Operation
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application
11.5.5.2. Market Revenue and Forecast, by End-User
11.5.5.3. Market Revenue and Forecast, by Scale of Operation
12.1. Thermo Fisher Scientific
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Oxford Biomedica
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Miltenyi Biotec
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Charles River Laboratories
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Catalent Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Fujifilm Diosynth Biotechnologies
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cytiva
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Takara Bio Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Vigene Biosciences (part of Charles River)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Bluebird Bio
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
